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doi:10.1016/j.fjs.2011.08.007Summary Thymic carcinoma is a rare but highly aggressive, easily metastasizing cancer
derived from thymic epithelial cells and has a very poor prognosis. Unlike thymoma, which
is usually found because it is associated with paraneoplastic syndrome, thymic carcinoma is
almost always found at an advanced stage because patients often have atypical symptoms.
There is no known tumor marker for thymic carcinoma screening. Because most tumors are
discovered at an advanced stage, the Masaoka staging system, which is widely used for thymo-
ma, is of questionable value for thymic carcinoma. Complete resection of the tumor is the
mainstay of treatment and leads to the best survival rate for patients. However, the complete
resection rate is only approximately 50% and the recurrence rate after complete resection is
high, up to 40%. The role of postoperative radiotherapy or chemotherapy is still controversial.
For tumors that cannot be completely resected, the result of debulking surgery is not different
from that of a biopsy. The efficacy of preoperative radiotherapy, chemotherapy, or concurrent
chemoradiation therapy is still debatable because most studies on these topics were for only
a small number of patients and were retrospective in nature. The overall 5-year survival rate
for patients with thymic carcinoma is only 30e50%. A prospective randomized study requires
multi-center collaboration and the establishment of an optimal treatment protocol to increase
the survival rate of patients with thymic carcinoma, for which there is no predictive screening
biomarker or a suitable staging system at present.
Copyright ª 2011, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.horacic Surgery, Department of Surgery, National Cheng Kung University Hospital, 138 Sheng-Li Road,
.edu.tw.
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Thymic carcinoma, a cancer derived from thymic epithelial
cells, was first recognized by Shimosato et al in 1977 in their
study of squamous cell carcinoma of the thymus.1 Additional
variables of thymic carcinoma were reported in a later study
by Snover et al in 1982.2 The relationship between thymoma
and thymic carcinoma is still controversial. The adeno-
maecarcinoma model in other solid organ malignancies,
a term that describes the stepwise progression from normal
to dysplastic epithelium to carcinoma associated with the
accumulation of multiple clonally selected genetic
alterations,3 cannot be applied to thymoma and thymic
carcinoma because thymoma may recur and metastasize
without any overt cytological features of malignancy. Most
articles in the literature suggest that thymic carcinoma
occurs de novo from thymic epithelial cells instead of from
thymoma.4,5 In 1999, histologic classification of thymic
epithelial tumors according to the World Health Organiza-
tion (WHO) relied on histological assessment of the
morphology of neoplastic epithelial cells and the relative
amount of a non-neoplastic lymphocytic component. The
term type C thymoma was introduced to stress the thymic
epithelial origin of carcinomas.6 Neuroendocrine carcinoma
consisting of carcinoid, atypical carcinoid, and small- and
large-cell carcinoma was included in type C thymoma in the
newly defined WHO histological classification in 2004.7
Thymic carcinoma (type C thymoma), unlike thymoma,
exhibits distinctly more aggressive behavior and a much
poorer prognosis.5 Articles in the literature describing
thymic carcinoma are relatively rare. This review addresses
issues in relation to thymic carcinoma that require specific
attention.
2. Incidence of thymic carcinoma
The first report on a large number of cases (n Z 60) with
thymic carcinoma was published in 1991 by Suster and
Rosai.8 In 2003, Kondo and Monden9 reported the largest
series, consisting of 227 cases collected from 115 institu-
tions in Japan. Reports of more than 20 cases of thymic
carcinoma from a single institution are rare.10 According to
the literature, the incidence of thymic carcinoma is only
0.06% of all thymic neoplasms.10 We have retrospectively
reviewed reports on several large series on thymic
carcinoma11e21 and the results are summarized in Table 1.
We found that the incidence of thymic carcinoma
might have geographic differences. Confirmation of such
differences requires additional investigation of this rela-
tively rare cancer. We retrospectively reviewed our expe-
rience in treating 207 patients with thymic epithelial
tumors from June 1988 to November 2009. Some 37% of
these patients had thymic carcinoma. We are still investi-
gating the reason for such a high incidence of thymic
carcinoma in the southwest part of Taiwan.
3. Signs and symptoms of thymic carcinoma
Thymic carcinoma occurs most frequently in adults
between 30 and 60 years of age.5,8,10 In some cases, thymiccarcinoma is found incidentally on routine chest X-rays (20%
in our series). Once a patient has symptoms, which are
usually atypical chest symptoms due to mediastinal
compression or invasion (53% in our series), the cancer is
already at an advanced stage. Because of the anterior
mediastinal location and high invasiveness, the superior
vena cava syndrome is not rare. A paraneoplastic syndrome
has also been reported for patients with thymic carcinoma,
but is rare. Pure red cell aplasia or hyper- or hypo-
globulinemia occurs primarily in thymoma rather than in
thymic carcinoma.10 Myasthenia gravis is commonly found
in patients with thymoma, but rarely occurs in patients
with thymic carcinoma unless there is a concomitant thy-
moma component.9,10,20 We previously described one
patient with thymic carcinoid combined with myasthenia
gravis.22 Cushing syndrome and multiple endocrine
neoplasia type I have also been reported in patients
with thymic carcinoid.9,23 Pan et al reported that
thymoma has a higher incidence of associated malignancy,
which suggests a forgotten associated paraneoplastic
syndrome.24 It has also been suggested that the risk of
a second malignancy in thymoma patients is intrinsic and
unrelated to other oncogenic factors.24 We have found
that thymic carcinoma, especially neuroendocrine carci-
noma, also has a higher incidence of associated malig-
nancy.25 Thus, long-term follow-up of patients harboring
thymic carcinoma is recommended. Because most patients
with thymic carcinoma are identified at an advanced stage
without specific signs or symptoms, finding a biomarker for
early detection of this egregious cancer is of paramount
importance.
4. Histology and specific stains for differential
diagnosis
According to the WHO classification, type C thymoma
comprises a large number of histological types of thymic
carcinoma.5,7,8 Because most of these cancers clinically
resemble cancers from other organ sites, thymic carcinoma
should always be a diagnosis of exclusion.5,7 Metastasis
from other organs should be ruled out before establishing
the diagnosis. Differentiation of thymic carcinoma from
cancer metastasized from other organs is still difficult. It
has been reported that lymphoid markers expressed in the
tumor cells of thymic carcinoma, such as CD5 and CD70,
are markers for differential diagnosis; however, they are
valid only for differentiating thymic carcinoma from thy-
moma.5,26,27 Overexpression of c-kit (CD117) in thymic
carcinoma is a promising finding28,29 because most types
of thymoma and squamous cell carcinomas from other
organ systems do not express this marker, and squamous
cell carcinoma is the most common type of thymic
carcinoma.5,9
5. Staging
The Masaoka staging system is the most popular and most
widely accepted system for staging and predicting thy-
moma prognosis.9,12,15,30 However, because most patients
with thymic carcinoma are at an advanced stage (in our
Table 1 Incidence of WHO histological subtypes from a large series of reports on thymoma
Ref Patients (n) Country Incidence, n (%)
A AB B1 B2 B3 C
12 108 Korea 7 (6.5) 25 (23.1) 12 (11.1) 32 (29.6) 20 (18.5) 12 (11.1)
13 132 Italy 14 (10.6) 31 (23.5) 20 (15.1) 28 (21.2) 29 (22.0) 10 (7.6)
14 195 Korea 9 (4.6) 37 (19.0) 29 (14.9) 48 (24.6) 40 (20.5) 32 (16.4)
11 204 China 8 (3.9) 64 (31.3) 17 (8.3) 36 (17.6) 31 (15.2) 39 (19.1)
15 200 China 8 (4.0) 68 (34.0) 17 (8.5) 39 (19.5) 27 (13.5) 36 (18.0)
19 218 Germany 43 (19.7) 20 (9.2) 24 (11.1) 82 (37.6) 10 (4.6) 39 (17.9)
16 152 USA 9 (5.9) 31 (20.4) 12 (7.9) 35 (22.4) 26 (10.3) 9 (5.9)
31 156 Denmark 24 (15.3) 46 (29.5) 1 (0.6) 35 (22.4) 16 (10.3) 32 (20.5)
17 116 USA 8 (6.9) 32 (27.6) 20 (17.2) 21 (18.1) 29 (25.0) 2 (1.7)
21 100 Japan 8 (8.0) 17 (17.0) 27 (27.0) 8 (8.0) 12 (12.0) 28 (28.0)
18 100 Japan 10 (10.0) 15 (15.0) 18 (18.0) 21 (21.0) 33 (33.0) 3 (3.0)
33 207 Taiwan 10 (4.8) 32 (15.5) 18 (8.7) 40 (19.3) 29 (14.0) 78 (37.7)
Figure 1 Cumulative survival over time. There was no
significant difference in overall survival rate among three
histological types of thymic carcinoma, which included squa-
mous cell carcinoma (SCC; n Z 59), lymphoepithelioma-like
carcinoma (LE; n Z 10) and neuroendocrine tumors (NE;
n Z 8), in our series (p Z 0.418).
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in Stage III and 29 patients in Stage IV), the usefulness of
Masaoka staging for thymic carcinoma is doubtful.32,33
Blumberg et al reported that tumor invasion of brachioce-
phalic vessels indicates a poor prognosis.32 We also found
that invasion of the great vessels indicated a poor prognosis
in thymic carcinoma.33 Unfortunately, both studies con-
tained some patients with type B3 thymoma. Although
invasion of the great vessels has been used in the Masaoka
staging system as a subcategory of Stage III,34 this has not
been well accepted in recent years. The tumor, node,
metastasis (TNM) system has been proposed for evaluating
thymoma.35 Although lymph node metastasis occurs more
frequently in thymic carcinoma than in thymoma, the
incidence is still low, which makes it difficult to apply the
TNM system to thymic carcinoma. A new refined staging for
precisely predicting the prognosis of thymic carcinoma is
required.
6. Treatment
Thymic carcinoma in most cases is diagnosed at an
advanced stage. According to the literature, the 5-year
survival rate for thymic carcinoma is 30e50%.12,15,20 In our
series, the overall survival rate for three common histo-
logical types of thymic carcinoma, including squamous cell
carcinoma, lymphoepithelioma-like carcinoma and neuro-
endocrine tumors, was similar to that in the literature
(Figure 1). The survival rate did not significantly differ for
these histological types of thymic carcinoma. Complete
resection of the tumor is still the mainstay of treat-
ment.9,12,13,16,18,19 It has been reported that the complete
resection rate is approximately 50% (range 17e67%), but
the recurrence rate is still high (40% in our series), even
after complete resection.9,10,33 Postoperative radiation
therapy does not seem to benefit survival, but may reduce
the local recurrence rate.9,20,36 The efficacy of adjuvant
chemotherapy is still obscure.20,33 Although debulking
surgery might be beneficial for advanced thymoma, it has
shown no benefit for thymic carcinoma. The survival rate
was not different between patients who underwentdebulking surgery and those who were simply biop-
sied.9,33,36,37 Because most thymic carcinoma patients are
diagnosed at an advanced stage, induction chemotherapy
or concurrent chemoradiation therapy should be used first
in an attempt to down-stage the tumor for surgery.
However, results for this strategy are still con-
troversial.33,36e40 Most published studies on thymic carci-
noma had a small number of patients and were neither
prospective nor randomized.20 Moreover, the regimens for
treatment were heterogeneous. An optimal treatment
protocol for the disease has yet to be defined.20 Most
reports from Taiwan show dismal results for thymic
carcinoma treated with concurrent chemoradiation
therapy.33,36,37 Target therapy, such as that using a c-kit
inhibitor, has produced promising results in treating thymic
carcinoma41; however, large-scale studies are necessary to
confirm the therapeutic results.
Thymic carcinoma 1397. Summary
Thymic carcinoma requires special attention because the
following are lacking: (1) a biomarker for early detection;
(2) an acceptable prognostic factor for predicting prognosis;
(3) a suitable staging system for predicting prognosis; and
(4) prospective randomized studies to establish an optimal
treatment protocol. Because thymic carcinoma is mostly
found at an advanced stage and because this cancer is rare,
multi-center collaboration and prospective randomized
studies are needed before a more comprehensive treat-
ment protocol for this highly aggressive malignancy can be
developed.
Acknowledgment
I am grateful to Professor Ming-Ho Wu for providing the
figure and table for this manuscript.
References
1. Shimosato Y, Kameya T, Nagaki K, Suemasu K. Squamous cell
carcinoma of the thymus. An analysis of eight cases. Am J Surg
Pathol. 1977;1:109e121.
2. Snover DC, Levine GD, Rosai J. Thymic carcinoma. Five distinc-
tive histological variants. Am J Surg Pathol. 1982;6:451e470.
3. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal ade-
nomaecarcinoma sequence. Br J Surg. 2002;89:845e860.
4. Hasserjian RP, Strobel P, Marx A. Pathology of thymic tumors.
Semin Thorac Cardiovasc Surg. 2005;17:2e11.
5. Suster S. Thymic carcinoma: update of current diagnostic
criteria and histologic types. Semin Diagn Pathol. 2005;22:
198e212.
6. Rosai J, Sobin LH. Histological typing of tumors of the thymus.
In: WHO international histological classification of tumors.
2nd ed. Berlin: Springer-Verlag; 1999. p. 1e65.
7. Marx A, Stro¨bel P, Zettl A, et al. Thymomas. In: Travis MD,
Brambilla E, Muller-Hermelink HK, Harris CC, editors.
Pathology and genetics of tumours of the lung, pleura, thymus
and heart. World Health Organization classification of
tumours, Vol 7. Lyon: IARC Press; 2004. p. 152e153.
8. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study
of 60 cases. Cancer. 1991;67:1025e1032.
9. Kondo K, Monden Y. Therapy for thymic epithelial tumors:
a clinical study of 1,320 patients from Japan. Ann Thorac Surg.
2003;76:878e884.
10. Chung DA. Thymic carcinomadanalysis of nineteen clinico-
pathological studies. Thorac Cardiovasc Surg. 2000;48:
114e119.
11. Fang W, Chen W, Chen G, Jiang Y. Surgical management of
thymic epithelial tumors: a retrospective review of 204 cases.
Ann Thorac Surg. 2005;80:2002e2007.
12. Kim DJ, Yang WI, Choi SS, Kim KD, Chung KY. Prognostic and
clinical relevance of the World Health Organization schema for
the classification of thymic epithelial tumors: a clinicopatho-
logic study of 108 patients and literature review. Chest. 2005;
127:755e761.
13. Rea F, Marulli G, Girardi R, et al. Long-term survival and
prognostic factors in thymic epithelial tumours. Eur J Car-
diothorac Surg. 2004;26:412e418.
14. Lee HS, Kim ST, Lee J, et al. A single institutional experience of
thymic epithelial tumours over 11 years: clinical features andoutcome and implications for future management. Br J Cancer.
2007;97:22e28.
15. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classi-
fication predicts prognosis of thymic epithelial tumors: a clini-
copathologic study of 200 thymoma cases from China. Cancer.
2002;95:420e429.
16. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF.
Thymoma. A clinicopathologic review. Cancer. 1987;60:
2727e2743.
17. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E,
Harris NL. Thymoma. Histologic subclassification is an inde-
pendent prognostic factor. Cancer. 1994;74:606e617.
18. Sonobe S, Miyamoto H, Izumi H, et al. Clinical usefulness of the
WHO histological classification of thymoma. Ann Thorac Car-
diovasc Surg. 2005;11:367e373.
19. Rieker RJ, Hoegel J, Morresi-Hauf A, et al. Histologic classifi-
cation of thymic epithelial tumors: comparison of established
classification schemes. Int J Cancer. 2002;98:900e906.
20. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR. Thymic
carcinoma: state of the art review. Int J Radiat Oncol Biol
Phys. 2004;59:654e664.
21. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic
classification is a prognostic indicator in thymoma. Ann Thorac
Surg. 2004;77:1183e1188.
22. Wu MH, Tseng YL, Cheng FF, Lin TS. Thymic carcinoid combined
with myasthenia gravis. J Thorac Cardiovasc Surg. 2004;127:
584e585.
23. Ferolla P, Falchetti A, Filosso P, et al. Thymic neuroendocrine
carcinoma (carcinoid) in multiple endocrine neoplasia type 1
syndrome: the Italian series. J Clin Endocrinol Metab. 2005;90:
2603e2609.
24. Pan CC, Chen PC, Wang LS, Chi KH, Chiang H. Thymoma is
associated with an increased risk of second malignancy.
Cancer. 2001;92:2406e2411.
25. Yen YT, Lai WW, Wu MH, et al. Thymic neuroendocrine carci-
noma and thymoma are both associated with increased risk of
extrathymic malignancy: a 20-year review of a single institu-
tion. Ann Thorac Surg. 2011;91:219e225.
26. Hishima T, Fukayama M, Fujisawa M, et al. CD5 expression in
thymic carcinoma. Am J Pathol. 1994;145:268e275.
27. Hishima T, Fukayama M, Hayashi Y, et al. CD70 expression in
thymic carcinoma. Am J Surg Pathol. 2000;24:742e746.
28. Pan CC, Chen PC, Chiang HKIT. (CD117) is frequently overex-
pressed in thymic carcinomas but is absent in thymomas.
J Pathol. 2004;202:375e381.
29. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H,
Tsuchiya R. Immunohistochemical KIT (CD117) expression in
thymic epithelial tumors. Chest. 2005;128:140e144.
30. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study
of thymomas with special reference to their clinical stages.
Cancer. 1981;48:2485e2492.
31. Engel P, Marx A, Muller-Hermelink HK. Thymic tumours in
Denmark. A retrospective study of 213 cases from 1970e1993.
Pathol Res Pract. 1999;195:565e570.
32. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma:
current staging does not predict prognosis. J Thorac Cardiovasc
Surg. 1998;115:303e308.
33. Tseng YL, Wang ST, Wu MH, Lin MY, Lai WW, Cheng FF. Thymic
carcinoma: involvement of great vessels indicates poor prog-
nosis. Ann Thorac Surg. 2003;76:1041e1045.
34. Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J,
editor. Atlas of tumor pathology. 3rd ed. Washington, DC:
Armed Forces Institute of Pathology; 1997. p. 93e115.
35. Yamakawa Y, Masaoka A, Hashimoto T, et al. A tentative
tumor-node-metastasis classification of thymoma. Cancer.
1991;68:1984e1987.
140 Y.-L. Tseng36. Liu HC, Hsu WH, Chen YJ, et al. Primary thymic carcinoma. Ann
Thorac Surg. 2002;73:1076e1081.
37. Lin JT, Wei-Shu W, Yen CC, Liu JH, Chen PM, Chiou TJ. Stage IV
thymic carcinoma: a study of 20 patients. Am J Med Sci. 2005;
330:172e175.
38. Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy
for advanced thymic carcinoma: clinical response to
cisplatin, doxorubicin, vincristine, and cyclophosphamide
(ADOC chemotherapy). Am J Clin Oncol. 2002;25:266e268.39. Weide LG, Ulbright TM, Sr Loehrer PJ, Williams SD. Thymic
carcinoma. A distinct clinical entity responsive to chemo-
therapy. Cancer. 1993;71:1219e1223.
40. Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma. Ten years’
experience in twenty patients. J Thorac Cardiovasc Surg. 1994;
107:615e620.
41. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with
overexpression of mutated KIT and the response to imatinib.
N Engl J Med. 2004;350:2625e2626.
